SCHEMBL5632191

SCHEMBL5632191

O=C(NCC1CC1)c1ccc(Br)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 7/20 0.55
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
HDAC6 Q9UBN7 4/20 0.51
HDAC3 O15379 2/20 0.51
HDAC4 P56524 2/20 0.51
HDAC1 Q13547 2/20 0.51
HDAC7 Q8WUI4 2/20 0.51
HDAC2 Q92769 2/20 0.51
HDAC10 Q969S8 2/20 0.51
HDAC11 Q96DB2 2/20 0.51
HDAC8 Q9BY41 2/20 0.51
HDAC9 Q9UKV0 2/20 0.51
HDAC5 Q9UQL6 2/20 0.51
CYP2C9 P11712 2/20 0.51
AR P10275 1/20 0.48
IDO1 P14902 1/20 0.48
TDO2 P48775 1/20 0.48
MLYCD O95822 1/20 0.48
MCHR1 Q99705 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25227433 0.83 KMT2A (0.58) MAPK14MEN1KMT2AHDAC6HDAC3
SCHEMBL31006908 0.83 KMT2A (0.58) MAPK14MEN1KMT2AHDAC6HDAC3
SCHEMBL5630409 0.82 MAPK14 (0.66) MAPK14CYP2C9MAPK11
SCHEMBL4262877 0.80 MAPK14 (0.56) MAPK14MEN1KMT2AHDAC6HDAC3
SCHEMBL3455181 0.80 MAPK14 (0.56) MAPK14MEN1KMT2AHDAC6HDAC3
SCHEMBL3130723 0.79 HDAC6 (0.62) MAPK14MEN1KMT2AHDAC6AR
SCHEMBL5630219 0.78 HDAC3 (0.62) MAPK14MEN1KMT2AHDAC6HDAC3
SCHEMBL29926296 0.78 HDAC6 (0.59) MAPK14KMT2AHDAC6HDAC3HDAC4
SCHEMBL3231353 0.77 HDAC6 (0.59) MAPK14MEN1KMT2AHDAC6MLYCD
SCHEMBL29115579 0.77 HPGD (0.55) MAPK14HDAC6HDAC1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208629-B2 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-04-24 US disclosed
US-20040267012-A1 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2004-12-30 US disclosed
EP-1435936-A1 5'-CARBAMOYL-1,1-BIPHENYL-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-14 EP disclosed
WO-2003032972-A1 5’-CARBAMOYL-1,1-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267012-A1 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors MAPK4, GRK4, NR4A1 MAPK14 28/4885MEN1 3787/4885KMT2A 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.